Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Expects To Benefit From Consolidation Driven By "Authorized" Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

Generic firms with smaller pipelines will feel pressure from authorized generics, CEO Makov says. Teva will not pursue a Mylan/King type of acquisition to boost its brand business because "we are doing very well in generics," the exec says.

You may also be interested in...



“Authorized” Generics Fight Moves To Capitol Hill, FTC

Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.

“Authorized” Generics Fight Moves To Capitol Hill, FTC

Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.

King To Set Aside Additional $65 Mil. To Settle SEC/OIG Investigation

The company’s Medicaid underpayment liability is approximately $130 mil. King says its wholesaler inventory levels have begun to normalize with 2.4 months of Rx demand across its four key products.

Related Content

Topics

UsernamePublicRestriction

Register

PS060483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel